-
公开(公告)号：US20140271458A1
公开(公告)日：2014-09-18
申请号：US14211604
申请日：2014-03-14
Applicant: AbbVie Inc.
Inventor： Tariq Ghayur , JiJie Gu , Maria Harris , Carrie Goodreau , Sonal Saluja
CPC classification number: C07K16/468 , A61K39/3955 , A61K45/06 , A61K47/6845 , A61K47/6879 , C07K16/244 , C07K16/245 , C07K2317/31 , C07K2317/626 , C07K2317/64 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/00 , G01N33/6869 , G01N2333/54 , G01N2333/545
Abstract: Engineered multivalent and multispecific binding proteins that bind IL-1β and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.
-
公开(公告)号：US20140093521A1
公开(公告)日：2014-04-03
申请号：US14090778
申请日：2013-11-26
Applicant: ABBVIE INC.
Inventor： Lorenzo Benatuil , Erwin R. Boghaert , Jijie Gu , Maria Harris , Jonathan A. Hickson , Chung-Ming Hsieh , Yuliya Kutskova , Yingchun Li , Zhihong Liu , Susan Morgan-Lappe
IPC: A61K39/395 , A61K45/06 , C07K16/18 , C07K7/06 , C07K7/08
CPC classification number: C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K7/06 , C07K7/08 , C07K14/47 , C07K16/18 , C07K2317/21 , C07K2317/33 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
Abstract translation: 描述了改进的DLL4结合蛋白，包括抗体，CDR-移植抗体，人抗体和DLL4结合片段，以高亲和力结合DLL4的蛋白质，以及中和DLL4活性的DLL4结合蛋白。 DLL4结合蛋白可用于治疗或预防癌症和肿瘤，特别是用于治疗或预防肿瘤血管生成和/或其它血管发生依赖性疾病，例如眼新生血管形成或以异常DLL4表达或活性为特征的血管发生非依赖性疾病，例如自身免疫 包括多发性硬化的疾病。
-
公开(公告)号：US20180371071A1
公开(公告)日：2018-12-27
申请号：US15582065
申请日：2017-04-28
Applicant: AbbVie Inc.
Inventor： Lorenzo Benatuil , Erwin R. Boghaert , Jijie Gu , Maria Harris , Jonathan A. Hickson , Chung-Ming Hsieh , Yuliya Kutskova , Yingchun Li , Zhihong Liu , Susan Morgan-Lappe
Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
-
公开(公告)号：US20160060332A1
公开(公告)日：2016-03-03
申请号：US14822329
申请日：2015-08-10
Applicant: Abbvie Inc.
Inventor： Lorenzo Benatuil , Erwin R. Boghaert , Jijie Gu , Maria Harris , Jonathan A. Hickson , Chung-Ming Hsieh , Yuliya Kutskova , Yingchun Li , Zhihong Liu , Susan Morgan-Lappe
IPC: C07K16/22
CPC classification number: C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K7/06 , C07K7/08 , C07K14/47 , C07K16/18 , C07K2317/21 , C07K2317/33 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
Abstract translation: 描述了改进的DLL4结合蛋白，包括抗体，CDR-移植抗体，人抗体和DLL4结合片段，以高亲和力结合DLL4的蛋白质，以及中和DLL4活性的DLL4结合蛋白。 DLL4结合蛋白可用于治疗或预防癌症和肿瘤，特别是用于治疗或预防肿瘤血管生成和/或其它血管发生依赖性疾病，例如眼新生血管形成或以异常DLL4表达或活性为特征的血管发生非依赖性疾病，例如自身免疫 包括多发性硬化的疾病。
-
5.发明申请公开(公告)号：US20150344590A1
公开(公告)日：2015-12-03
申请号：US14713251
申请日：2015-05-15
Applicant: ABBVIE INC.
Inventor： Tariq Ghayur , JiJie Gu , Maria Harris , Carrie Goodreau , Sonal Saluja
CPC classification number: C07K16/468 , A61K39/3955 , A61K45/06 , A61K47/6845 , A61K47/6879 , C07K16/244 , C07K16/245 , C07K2317/31 , C07K2317/626 , C07K2317/64 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/00 , G01N33/6869 , G01N2333/54 , G01N2333/545
Abstract: Engineered multivalent and multispecific binding proteins that bind IL-1β and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.
Abstract translation: 结合IL-1和bgr的工程化多价和多特异性结合蛋白 和/或IL-17，以及在预防，诊断和/或治疗疾病中的制备和用途的方法。
-
Patent Agency Ranking
公开(公告)号：US09469688B2
公开(公告)日：2016-10-18
申请号：US14822329
申请日：2015-08-10
Applicant: ABBVIE INC.
Inventor： Lorenzo Benatuil , Erwin R. Boghaert , Jijie Gu , Maria Harris , Jonathan A. Hickson , Chung-Ming Hsieh , Yuliya Kutskova , Yingchun Li , Zhihong Liu , Susan Morgan-Lappe
IPC: C07H21/04 , C07K16/22 , C07K14/47 , C07K16/18 , A61K39/395 , A61K45/06 , C07K7/06 , C07K7/08 , A61K39/00
CPC classification number: C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K7/06 , C07K7/08 , C07K14/47 , C07K16/18 , C07K2317/21 , C07K2317/33 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
-
公开(公告)号：US09132190B2
公开(公告)日：2015-09-15
申请号：US14090778
申请日：2013-11-26
Applicant: AbbVie Inc.
Inventor： Lorenzo Benatuil , Erwin R. Boghaert , Jijie Gu , Maria Harris , Jonathan A. Hickson , Chung-Ming Hsieh , Yuliya Kutskova , Yingchun Li , Zhihong Liu , Susan Morgan-Lappe
CPC classification number: C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K7/06 , C07K7/08 , C07K14/47 , C07K16/18 , C07K2317/21 , C07K2317/33 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
Abstract translation: 描述了改进的DLL4结合蛋白，包括抗体，CDR-移植抗体，人抗体和DLL4结合片段，以高亲和力结合DLL4的蛋白质，以及中和DLL4活性的DLL4结合蛋白。 DLL4结合蛋白可用于治疗或预防癌症和肿瘤，特别是用于治疗或预防肿瘤血管生成和/或其它血管发生依赖性疾病，例如眼新生血管形成或以异常DLL4表达或活性为特征的血管发生非依赖性疾病，例如自身免疫 包括多发性硬化的疾病。
-
8.发明授权公开(公告)号：US08987418B2
公开(公告)日：2015-03-24
申请号：US14323627
申请日：2014-07-03
Applicant: AbbVie Inc.
Inventor： Tariq Ghayur , JiJie Gu , Maria Harris , Carrie Goodreau , Sonal Saluja
CPC classification number: C07K16/468 , A61K39/3955 , A61K45/06 , A61K47/6845 , A61K47/6879 , C07K16/244 , C07K16/245 , C07K2317/31 , C07K2317/626 , C07K2317/64 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/00 , G01N33/6869 , G01N2333/54 , G01N2333/545
Abstract: Engineered multivalent and multispecific binding proteins that bind IL-1β and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.
Abstract translation: 结合IL-1和bgr的工程化多价和多特异性结合蛋白 和/或IL-17，以及在预防，诊断和/或治疗疾病中的制备和用途的方法。
-
公开(公告)号：US20200255508A1
公开(公告)日：2020-08-13
申请号：US16576078
申请日：2019-09-19
Applicant: AbbVie Inc.
Inventor： Lorenzo Benatuil , Erwin R. Boghaert , Jijie Gu , Maria Harris , Jonathan A. Hickson , Chung-Ming Hsieh , Yuliya Kutskova , Yingchun Li , Zhihong Liu , Susan Morgan-Lappe
Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
-
10.发明授权公开(公告)号：US09062108B2
公开(公告)日：2015-06-23
申请号：US14211604
申请日：2014-03-14
Applicant: AbbVie Inc.
Inventor： Tariq Ghayur , JiJie Gu , Maria Harris , Carrie Goodreau , Sonal Saluja
CPC classification number: C07K16/468 , A61K39/3955 , A61K45/06 , A61K47/6845 , A61K47/6879 , C07K16/244 , C07K16/245 , C07K2317/31 , C07K2317/626 , C07K2317/64 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/00 , G01N33/6869 , G01N2333/54 , G01N2333/545
Abstract: Engineered multivalent and multispecific binding proteins that bind IL-1β and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.
Abstract translation: 结合IL-1和bgr的工程化多价和多特异性结合蛋白 和/或IL-17，以及在预防，诊断和/或治疗疾病中的制备和用途的方法。
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.05 seconds)
